Semaglutide gut transit: a 13C breath test

This article is for educational and journalistic purposes only. It does not constitute medical advice. If you are on semaglutide and have questions about gastrointestinal symptoms, speak with your prescribing clinician.

Why gut transit matters for semaglutide users

One of the known pharmacological effects of GLP-1 receptor agonists like semaglutide is slowed gastric emptying. Food leaves the stomach more slowly, which contributes to the prolonged fullness many patients report. The clinical flip side is that delayed transit can cause nausea, constipation, and in the perioperative setting, retained solid gastric contents that raise aspiration risk even after a standard fast^[2]. The effect is real and clinically consequential, yet researchers have lacked a convenient, noninvasive tool to measure it quantitatively in preclinical models without restraining the animal or using radioactive tracers.

A study published in the American Journal of Physiology: Endocrinology and Metabolism on 20 August 2026 addresses that measurement gap^[1]. The work, led by Vieira, Langmeyer, Cortopassi, and colleagues at Harvard-affiliated institutions, describes a 13C-labeled mannitol breath test capable of tracking oral-cecal transit time (OCTT) in unrestrained mice receiving semaglutide.

What the 13C-mannitol breath test does

The principle relies on a simple biological fact: mannitol, a sugar alcohol, is not absorbed in the small intestine. It passes through intact until it reaches the large intestine, where resident bacteria ferment it and produce carbon dioxide. By labeling mannitol with the stable isotope 13C and measuring the ratio of 13CO2 to ordinary 12CO2 in exhaled breath, the researchers could detect the moment fermentation begins and therefore estimate when the labeled substrate arrived at the cecum^[1].

The team combined this approach with indirect calorimetry equipment already used to measure metabolic rate in living animals. Because indirect calorimetry continuously samples breath gases in real time, adding a 13C/12C isotope ratio measurement converts the same apparatus into a transit-time monitor. The result is what the authors call a highly granular, noninvasive method to measure OCTT that works in unrestrained animals throughout their normal daily activity^[1].

What the test revealed about semaglutide in mice

When mice received semaglutide, the breath test detected a measurable delay in oral-cecal transit compared with untreated controls. The labeled 13CO2 signal appeared later in the breath curve, indicating that the fermentable substrate was taking longer to travel from mouth to cecum. The approach allowed longitudinal measurement in the same animals over time without sedation, surgical implants, radioactive labels, or the stress responses that can themselves alter gut motility^[1].

This matters for preclinical research because gut transit is one of the physiological parameters most likely to confound metabolic and pharmacological studies. If a drug slows transit, it changes how nutrients are absorbed, how gut hormones are released, and how the animal's caloric balance registers over any given period. Having a method that captures this in real time, without altering the experiment, closes a measurement gap that has been a practical limitation in GLP-1 preclinical work.

The clinical picture behind the mouse model

The mouse findings are a preclinical tool story, not a human outcome story. But the clinical context they sit in is well established. A 2026 prospective, matched-control study published in Anaesthesia found that among 43 patients on semaglutide who underwent elective surgery after a standard fast, 49% had a full stomach on gastric ultrasound, compared with 18% of matched controls not on the drug. Solid gastric contents were present in 42% of semaglutide patients versus 7% of controls, and the delay persisted even after withholding one administration of the drug^[2]. Anaesthesiologists in that study recommended individualised ultrasound-guided assessment for patients on GLP-1 agonists before any general anaesthetic.

The STEP-1 registration trial (Wilding et al., NEJM 2021, n=1,961 adults), which established semaglutide 2.4 mg as an obesity treatment with a mean body-weight reduction of 14.9% at 68 weeks, reported that nausea and diarrhoea were the most common adverse events with semaglutide and were typically transient and mild to moderate in severity^[3]. The GI signal is not new. What is new with the breath-test paper is a method that can track the underlying motility effect with precision in preclinical experiments.

What we do not yet know

The 2026 breath-test study is a methodological report in mice. Several open questions follow from it. Whether the method translates to human gut transit monitoring is not established. Whether the degree of OCTT delay seen in mice on semaglutide corresponds quantitatively to the delay measured by gastric ultrasound in human patients has not been tested. How transit time changes across the semaglutide dose range, and whether it normalises at steady state or persists throughout treatment, are questions the method could now help answer in future work.

For anyone currently on semaglutide and experiencing GI symptoms, the responsible framing is the same as before this study: nausea and constipation are known, dose-dependent class effects addressed by slow titration. If you are scheduled for a procedure requiring general anaesthesia, your anaesthetic team should know you are on a GLP-1 receptor agonist. The regulatory status of semaglutide in your country is on the semaglutide peptide page. Per-country prescribing and access detail is on the relevant regulation pages.